Personalized chemotherapy for hepatocellular carcinoma

Advances in Predictive, Preventive and Personalised Medicine

Volumn 8, Issue , 2015, Pages 53-60

  Hazin, Hesham ^a   Dosik, David ^a,b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BETA CATENIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ALCOHOL ABUSE; ARTICLE; ASPERGILLUS; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD PUGH SCORE; DIARRHEA; FATIGUE; HAND FOOT SYNDROME; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL;

EID: 84992063503     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: 10.1007/978-3-319-12166-6_6     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Rampone B, Schiavone B, Martino A et al (2009) Current management strategy of hepatocellular carcinoma. World J Gastroenterol 15:3210-3216
3. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:347-354
4. Tsai W-L, Chung RT (2010) Viral hepatocarcinogenesis. Oncogene 29:2309-2324
5. Torres DM, Harrison SA (2012) Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 32:30-38
6. Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7:237-257
7. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208- 1236
8. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908-943
9. Olweny CL, Toya T, Katongole-Mbidde E et al (1975) Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36:1250
10. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A et al (1984) Doxorubicin (75 mg/ m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 68:487.h
11. Ihde DC, Kane RC, Cohen MH et al (1977) Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61:1385
12. Nerenstone SR, Ihde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15:1
13. Lai CL, Wu PC, Chan GC et al (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479
14. Choi TK, Lee NW, Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53:401
15. Yeo W, Mok TS, Zee B et al (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532
16. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L (1985) Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 56:2751
17. Gish RG, Porta C, Lazar L et al (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069
18. Porta C, Moroni M, Nastasi G, Arcangeli G (1995) 5-Fluorouracil and d, l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 52:487
19. Tetef M, Doroshow J, Akman S et al (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460
20. Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851
21. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378
22. Vincenzi B, Santini D, Russo A et al (2010) Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15:85
23. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 10:25
24. Raoul J, Santoro A, Beaugrand M et al (2008) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial (abstract). J Clin Oncol 26:234 s. www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34874/. Accessed 4 May, 2009